Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$5.08M | -$5.00M | -$14.1M | -$23.0M | -$31.7M | -$24.5M | -$24.8M | -$21.4M | -$11.7M | -$9.95M |
| Net income | -$4.98M | -$4.95M | -$13.9M | -$23.3M | -$31.8M | -$24.5M | -$24.3M | -$17.2M | -$11.6M | -$10.3M |
| EPS (diluted) | — | — | -$0.70 | -$1.06 | -$1.07 | -$0.68 | -$0.66 | -$6.00 | -$2.31 | -$1.11 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.86M | -$2.36M | -$12.4M | -$11.2M | -$35.2M | -$26.3M | -$19.3M | -$20.5M | -$9.09M | -$6.97M |
| Capital expenditures | $103K | $180K | $369K | $473K | $378K | $330K | $29.0K | $18.0K | — | — |
| Free cash flow | -$5.96M | -$2.54M | -$12.8M | -$11.7M | -$35.6M | -$26.6M | -$19.3M | -$20.5M | — | — |
| Share buybacks | — | — | — | — | $116K | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $547K | $2.48M | $942K | $536K | $37.8M | $18.9M | $772K | $1.30M | $187K | $29.0K |
| Total assets | $10.8M | $11.4M | $11.2M | $6.53M | $51.3M | $29.3M | $8.45M | $4.21M | $1.83M | $1.02M |
| Total liabilities | $864K | $5.54M | $6.21M | $18.8M | $15.8M | $9.94M | $11.5M | $9.07M | $9.60M | $11.0M |
| Shareholders' equity | $9.90M | $5.88M | $5.02M | -$12.2M | $35.5M | $19.3M | -$3.02M | -$4.86M | -$7.76M | -$9.98M |
| Retained earnings | -$75.1M | -$80.1M | -$94.0M | -$117M | -$149M | -$174M | -$198M | -$215M | -$227M | -$237M |
| Shares (wtd avg diluted) | 18.7M | 19.0M | 20.8M | 23.2M | 29.8M | 36.2M | 36.5M | 2.87M | 5.02M | 9.27M |
Every figure is extracted from BRAINSTORM CELL THERAPEUTICS INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.